Most cited papers from NexImmune (United States)

NexImmune (United States)

What are the most cited papers from NexImmune (United States)?

The most cited paper from NexImmune (United States) is "Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study" (Christopher Edward Brightling, Eugene R. Bleecker, Reynold A. Panettieri et al., 2014), with 316 citations. Next come "Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease." (99) and "A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease" (97).

Published TypeFieldAccess

Showing 20 of 20 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study Christopher Edward Brightling, Eugene R. Bleecker, Reynold A. Panettieri et al. · The Lancet Respiratory Medicine Open access	7 Sep 2014	316
2	Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease. Scott Koenig, Robert M. Woods, Yambasu A. Brewah et al. · The Journal of Immunology	Oct 1993	99
3	A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease Peter M.A. Calverley, Sanjay Sethi, Michelle Dawson et al. · Respiratory Research Open access	9 Aug 2017	97
4	Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers BARBARA W. WHITE, Francisco León, Wendy I. White et al. · Clinical Therapeutics	Apr 2009	75
5	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells Junya Ichikawa, Tatsuya Yoshida, Ariel Isser et al. · Clinical Cancer Research Open access	2 Apr 2020	47
6	Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression Szilvia Bak, Sabine Tischer, Anna Christina Dragon et al. · Frontiers in Immunology Open access	17 Dec 2018	44
7	Cord blood–derived T cells allow the generation of a more naïve tumor‐reactive cytotoxic T‐cell phenotype Julian Kwoczek, Sebastian B. Riese, Sabine Tischer et al. · Transfusion	11 Oct 2017	40
8	Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. Robert van Kuyk, Bruce E. Torbett, Richard J. Gulizia et al. · The Journal of Immunology	Nov 1994	37
9	Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells Christian Schütz, Juan Carlos Varela, Karlo Perica et al. · Oncotarget Open access	Sep 2016	32
10	Blocking PD-1/PD-L1 in Genitourinary Malignancies Matthew C. Dallos, Charles G. Drake · The Cancer Journal	2018	27
11	AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties Lauren Suarez, Ruipeng Wang, Scott Carmer et al. · Transfusion Medicine and Hemotherapy Open access	2020	10
12	Soluble MHC class I complexes for targeted immunotherapy Anna Schappert, Jonathan P. Schneck, Lauren Suarez et al. · Life Sciences Open access	10 Aug 2018	7
13	AIM™ platform: A new immunotherapy approach for viral diseases David Langan, Ruipeng Wang, Keshanti Tidwell et al. · Frontiers in Medicine Open access	23 Dec 2022	3
14	PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy Hong Lou, David Langan, Nick Syracuse et al. · Neoplasia Open access	13 Apr 2026	2
15	A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy Hong Lou, David Langan, Nick Syracuse et al. · medRxiv PreprintOpen access	23 Jan 2026	1
16	Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness Manpreet Bariana, Sidharth R. Anand, Mark Batistick et al. · Blood Immunology & Cellular Therapy Open access	2 May 2025	1
17	A four-subtype model of cervical cancer based on PIK3CA mutation, STK11 mutation or deletion, and YAP1 amplification: Multiple PI3K pathway inhibitors as suppressors of growth and cooperators with HPV-directed immunotherapy. Michael Dean, Emma Robinson, Elisabeth Anne Murphy et al. · Journal of Clinical Oncology	28 May 2026	0
18	Targeted therapy to treat cervical cancer: Alpelisib, Inavolisib and Capivasertib, PI3-kinase and AKT inhibitors, suppresses PIK3CA mutated cervical cells and potentiate immunotherapy Sharon Wu, Michael Dean, Hong Lou et al. · Gynecologic Oncology	23 Apr 2026	0
19	Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses Monzr M. Al Malki, Miguel‐Angel Perales, Dipenkumar Modi et al. · Blood	5 Nov 2020	0
20	Rapid Expansion of Tumor-Specific T Cells Using Nanoparticle-Based Artificial Antigen Presenting Cells (aAPCs) Juan Carlos Varela, Christian Schuetz, Mathias Oelke et al. · Transplantation and Cellular Therapy Open access	18 Feb 2016	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.